Not Yet RecruitingPhase 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis.

China600 participantsStarted 2026-04

Plain-language summary

Phase III Efficacy and Safety Study of RSS0393 Ointment in Plaque Psoriasis.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Age must be ≥18 years on the day of signing the informed consent form, male or female.
✓. Body Mass Index (BMI = weight \[kg\] / height² \[m²\]) ≥18.0 kg/m² at screening.
✓. A history of plaque psoriasis for ≥6 months.
✓. Body Surface Area (BSA) involvement of psoriasis lesions between 2% and 20%, and a Psoriasis Area and Severity Index (PASI) score ≥2, and a Physician's Global Assessment (PGA) score ≥2 at both screening and baseline.

✕. Presence of any of the following skin abnormalities or conditions:
✕. Use of any of the following medications or participation in clinical studies:
✕.Presence of any significant medical histories or underlying conditions that may affect safety.
✕.Any of the following laboratory abnormalities and/or 12-lead ECG findings at screening/baseline:
✕. Hemoglobin \<100.0 g/L (for males) or \<90.0 g/L (for females);
✕. White blood cell count \<3.0 × 10⁹/L;
✕. Neutrophil count \<1.5 × 10⁹/L;
✕. Platelet count \<100 × 10⁹/L;

Achieving a Physician's Global Assessment (PGA) response at Week 8

Timeframe: week8

NCT IDNCT07543224

SponsorReistone Biopharma Company Limited

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-01

Shuang Li